49% year-on-year increase in net revenue
In the first half of 2024, LiveSpo recorded a 49% year-on-year growth in net revenue, mainly attributed to the company’s effective selling strategy in pharmacy chains and e-commerce channels. In May 2024, LiveSpo was granted two exclusive patents by the National Intellectual Property Office for LiveSpo COLON and LiveSpo X-SECRET. LiveSpo COLON supports the treatment of colitis, while LiveSpo X-SECRET supports the prevention and treatment of vaginitis.
LiveSpo, founded by three founders with combined experience in biotechnology, sales, and marketing, is a consumer health company manufacturing and selling liquid spore-based probiotics supplement, focusing on improving digestive health and enhancing respiratory function. Its nasal-spray spore probiotics, LiveSpo NAVAX, is one of LiveSpo’s most popular and highly efficacious products, offering safe respiratory treatment option to patients, particularly children, instead of using antibiotics.